<DOC>
	<DOCNO>NCT00211471</DOCNO>
	<brief_summary>To provide use Anecortave Acetate Sterile Suspension 15mg series five patient rubeosis iridis . Rubeosis iridis refers neovascularization iris . It cause number condition include , limited severe diabetic retinopathy , central retinal vein occlusion , chronic inflammation , infection . Anecortave acetate angiostatic , experimental drug test prevent growth blood vessel retina patient age-related macular degeneration ( AMD ) . Therefore , logical apply usage Anecortave patient ’ rubeosis iridis order reduce neovascularization stimulus cause regression abnormal iris vessel .</brief_summary>
	<brief_title>Treatment Rubeosis Iridis With Open-Label Anecortave Acetate Sterile Suspension ( 15 mg. ) .</brief_title>
	<detailed_description>Patients receive injection 15 mg Anecortave acetate behind eye treat ( “ study eye ” ) . They evaluate every six month determine condition stable worse . Following injection study medication , patient require come see study physician . The investigator study staff call patient day follow injection make sure adverse effect injection . Patients come Week 4 Month 3 follow-up visit . At Month 3 follow-up visit , patient show stability improvement , may offer either thermal laser Photodynamic Therapy . They remain study remain eligible repeat injection Anecortave Acetate Month 6 visit . Patients see Month 6 Re-treatment Evaluation Visit . If condition stable , offer re-injection study medication receive earlier . If Patients show stability improvement Month 6 visit , may offer thermal laser Photodynamic Therapy conjunction Anecortave Acetate injection . If patient re-injected 6 month visit , schedule follow-up visit repeat next 18 month . If patient opts re-injection , exit study .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Anecortave</mesh_term>
	<criteria>1 . Clinical diagnosis rubeosis iridis patient retinal ischemia . 2 . Patients must 18 year age older receive treatment . 3 . Visual acuity 20/30 20/320 Study Eye ETDRS visual acuity chart . 4 . Visual acuity 20/800 good Fellow Eye ETDRS visual acuity chart . 1 . Patient significantly compromise visual acuity study eye due concomitant ocular condition . 2 . Patients undergone intraocular surgery within last 2 month . 3 . Patient participate investigational drug study . 4 . Use investigational drug treatment relate unrelated condition within 30 day prior receipt study medication . 5 . Inability obtain photographs document CNV ( include difficulty venous access . 6 . Patient significant liver disease uremia . 7 . Patient known adverse reaction fluorescein indocyanine green iodine . 8 . Patient history medical condition would preclude schedule visit completion study . 9 . Patient insertion scleral buckle study eye . 10 . Patient receive radiation treatment . 11 . Patient pregnant nursing . 12 . Patient intravenous subcutaneous anticoagulant therapy , oral anticoagulant therapy ( exception aspirin antiplatelet therapy ) take 5day interruption therapy prior depot sham administration . 13 . Patient evidence scleral thin see time external eye exam time depot sham administration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
</DOC>